252 related articles for article (PubMed ID: 21969587)
1. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
2. LD Motif Recognition by Talin: Structure of the Talin-DLC1 Complex.
Zacharchenko T; Qian X; Goult BT; Jethwa D; Almeida TB; Ballestrem C; Critchley DR; Lowy DR; Barsukov IL
Structure; 2016 Jul; 24(7):1130-41. PubMed ID: 27265849
[TBL] [Abstract][Full Text] [Related]
3. CDK5 is a major regulator of the tumor suppressor DLC1.
Tripathi BK; Qian X; Mertins P; Wang D; Papageorge AG; Carr SA; Lowy DR
J Cell Biol; 2014 Dec; 207(5):627-42. PubMed ID: 25452387
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.
Chen L; Liu C; Ko FC; Xu N; Ng IO; Yam JW; Zhu G
J Biol Chem; 2012 Jul; 287(31):26104-14. PubMed ID: 22645138
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
6. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Qian X; Li G; Asmussen HK; Asnaghi L; Vass WC; Braverman R; Yamada KM; Popescu NC; Papageorge AG; Lowy DR
Proc Natl Acad Sci U S A; 2007 May; 104(21):9012-7. PubMed ID: 17517630
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.
Cao X; Voss C; Zhao B; Kaneko T; Li SS
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1455-60. PubMed ID: 22307599
[TBL] [Abstract][Full Text] [Related]
9. Concerted modulation of paxillin dynamics at focal adhesions by Deleted in Liver Cancer-1 and focal adhesion kinase during early cell spreading.
Kaushik S; Ravi A; Hameed FM; Low BC
Cytoskeleton (Hoboken); 2014 Dec; 71(12):677-94. PubMed ID: 25448629
[TBL] [Abstract][Full Text] [Related]
10. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
11. START-GAP1/DLC1 is localized in focal adhesions through interaction with the PTB domain of tensin2.
Kawai K; Kitamura SY; Maehira K; Seike J; Yagisawa H
Adv Enzyme Regul; 2010; 50(1):202-15. PubMed ID: 19895840
[No Abstract] [Full Text] [Related]
12. Effect of small interfering RNA transfection on FAK and DLC1 mRNA expression in OVCAR-3.
Shi H; Liu H; Zhao G
Mol Biol Rep; 2012 Oct; 39(10):9299-306. PubMed ID: 22760257
[TBL] [Abstract][Full Text] [Related]
13. Cancer-Associated Point Mutations in the
Wang D; Qian X; Sanchez-Solana B; Tripathi BK; Durkin ME; Lowy DR
Cancer Res; 2020 Sep; 80(17):3568-3579. PubMed ID: 32606003
[TBL] [Abstract][Full Text] [Related]
14. SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions.
Tripathi BK; Anderman MF; Qian X; Zhou M; Wang D; Papageorge AG; Lowy DR
J Cell Biol; 2019 Sep; 218(9):3060-3076. PubMed ID: 31308216
[TBL] [Abstract][Full Text] [Related]
15. Mechanotransduction in talin through the interaction of the R8 domain with DLC1.
Haining AWM; Rahikainen R; Cortes E; Lachowski D; Rice A; von Essen M; Hytönen VP; Del Río Hernández A
PLoS Biol; 2018 Jul; 16(7):e2005599. PubMed ID: 30028837
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor gene DLC1: Its modifications, interactive molecules, and potential prospects for clinical cancer application.
Ren G; Li G
Int J Biol Macromol; 2021 Jul; 182():264-275. PubMed ID: 33836193
[TBL] [Abstract][Full Text] [Related]
17. Tensin1 positively regulates RhoA activity through its interaction with DLC1.
Shih YP; Sun P; Wang A; Lo SH
Biochim Biophys Acta; 2015 Dec; 1853(12):3258-65. PubMed ID: 26427649
[TBL] [Abstract][Full Text] [Related]
18. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities.
Yang XY; Guan M; Vigil D; Der CJ; Lowy DR; Popescu NC
Oncogene; 2009 Mar; 28(11):1401-9. PubMed ID: 19151751
[TBL] [Abstract][Full Text] [Related]
19. [Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Feng Y; Zhou HX; Li JH; Li ZY; Cheng WG; Jin ML; He L
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1448-51. PubMed ID: 21868344
[TBL] [Abstract][Full Text] [Related]
20. Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells.
Shih YP; Takada Y; Lo SH
Mol Cancer Res; 2012 Jan; 10(1):34-9. PubMed ID: 22064653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
